Eric Topol

you know, I might take the implant, right?

So the problem is, you know, we don't have enough interest in this bioelectronic treatment.

And it's partly because the device industry, you know, overall has a tougher mission.

And you, in a way, have proven that, that, look, you had this hypothesis nailed 20, 30 years ago, and it's only taken until 2025 to finally have an FDA indication and a

a first tier, first rate randomized sham control trial.

So I thought I'd just get you to comment on what's it like to try to advance a hypothesis in the world of devices, because it just seems to be a much bigger obstacle.

Yeah, up until the GLP-1, Ozempic, Humira and the TNF blockers were the biggest drugs in the world for sales.

It shows you how big a deal autoimmune diseases are, the burden in our population.

So anyway, I just want to say, you know, the book is phenomenal, but

What's even more impressive, Kevin, is that you persevered and you tested the hypotheses and you led to breaking out of a new field.

And I just think it's in the early days.

I think there's gonna be a lot more autoimmune diseases

We're already seeing the randomized trial and refractory depression and other areas.

So anyway, congrats.

It's fun to discuss this with you.

I learned a lot, and I know everyone else who joined today did as well.

We'll post this with all the links that we've been talking about, and hopefully we'll have a chance to revisit all this progress in the times ahead.

So thanks very much, Kevin.

Well, thank you.

Keep up the great stuff.